1B1 Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Molecure S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł2.49 |
| 52 Week High | zł4.98 |
| 52 Week Low | zł2.00 |
| Beta | 2.2 |
| 11 Month Change | 7.34% |
| 3 Month Change | -27.02% |
| 1 Year Change | -34.61% |
| 33 Year Change | -69.73% |
| 5 Year Change | n/a |
| Change since IPO | -76.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1B1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 13.0% | 1.6% | 1.1% |
| 1Y | -34.6% | -19.0% | 7.2% |
Return vs Industry: 1B1 underperformed the German Pharmaceuticals industry which returned -18.3% over the past year.
Return vs Market: 1B1 underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| 1B1 volatility | |
|---|---|
| 1B1 Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1B1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1B1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 105 | Marcin Szumowski | molecure.com |
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program.
Molecure S.A. Fundamentals Summary
| 1B1 fundamental statistics | |
|---|---|
| Market cap | €38.73m |
| Earnings (TTM) | -€7.15m |
| Revenue (TTM) | €353.60k |
109.5x
P/S Ratio-5.4x
P/E RatioIs 1B1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1B1 income statement (TTM) | |
|---|---|
| Revenue | zł1.52m |
| Cost of Revenue | zł3.24m |
| Gross Profit | -zł1.72m |
| Other Expenses | zł29.04m |
| Earnings | -zł30.75m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.83 |
| Gross Margin | -112.84% |
| Net Profit Margin | -2,020.94% |
| Debt/Equity Ratio | 0% |
How did 1B1 perform over the long term?
See historical performance and comparison